UBS AM’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-398,540
| Closed | -$6.27M | – | 2898 |
|
|
2024
Q1 | $6.27M | Sell |
398,540
-1,504
| -0.4% | -$23.1K | ﹤0.01% | 1165 |
|
|
2023
Q4 | $6.45M | Sell |
400,044
-2,854
| -0.7% | -$36.4K | ﹤0.01% | 1145 |
|
|
2023
Q3 | $5.12M | Sell |
402,898
-13,408
| -3% | -$185K | ﹤0.01% | 1194 |
|
|
2023
Q2 | $6.43M | Hold |
416,306
| – | – | ﹤0.01% | 1126 |
|
|
2023
Q1 | $6.43M | Buy |
416,306
+380,355
| +1,058% | +$6.35M | ﹤0.01% | 1126 |
|
|
2022
Q4 | $589K | Sell |
35,951
-16,686
| -32% | -$271K | ﹤0.01% | 2111 |
|
|
2022
Q3 | $974K | Buy |
52,637
+2,126
| +4% | +$33.4K | ﹤0.01% | 1983 |
|
|
2022
Q2 | $664K | Buy |
50,511
+5,837
| +13% | +$64.4K | ﹤0.01% | 2169 |
|
|
2022
Q1 | $414K | Hold |
44,674
| – | – | ﹤0.01% | 2520 |
|
|
2021
Q4 | $436K | Sell |
44,674
-312,949
| -88% | -$5.89M | ﹤0.01% | 2604 |
|
|
2021
Q3 | $12.2M | Sell |
357,623
-35,355
| -9% | -$1.13M | 0.01% | 1020 |
|
|
2021
Q2 | $14.4M | Buy |
392,978
+107,177
| +38% | +$4.15M | 0.01% | 986 |
|
|
2021
Q1 | $12.8M | Sell |
285,801
-102,410
| -26% | -$4.77M | 0.01% | 998 |
|
|
2020
Q4 | $22.2M | Buy |
388,211
+104,822
| +37% | +$6.21M | 0.01% | 826 |
|
|
2020
Q3 | $14.5M | Buy |
283,389
+12,676
| +5% | +$621K | 0.01% | 853 |
|
|
2020
Q2 | $16.2M | Sell |
270,713
-12,689
| -4% | -$679K | 0.01% | 792 |
|
|
2020
Q1 | $11.7M | Sell |
283,402
-28,342
| -9% | -$1.57M | 0.01% | 819 |
|
|
2019
Q4 | $19.4M | Buy |
311,744
+84,745
| +37% | +$4.03M | 0.01% | 783 |
|
|
2019
Q3 | $7.7M | Buy |
+226,999
| New | +$6.72M | 0.01% | 1046 |
|
Other funds holding DCPH
UBS AM's DCPH Position: Q2 2024 in Review
UBS AM sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 398,540 shares — an estimated $6.27M sold.
UBS AM first reported a position in DCPH in Q3 2019 and held it in 19 quarters. The position peaked at $22.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- UBS AM reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- UBS AM sold 398,540 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $6.27M.
- UBS AM first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 19 quarters.
- UBS AM's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $22.2M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on UBS AM's 13F filing for Q2 2024, filed 14 Aug 2024.